Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Apontis Pharma AG
  6. News
  7. Summary
    APPH   DE000A3CMGM5

APONTIS PHARMA AG

(APPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : APONTIS PHARMA marks further success in the roll-out of Single Pill therapy

07/12/2021 | 01:31am EDT
DGAP-News: APONTIS PHARMA AG / Key word(s): Alliance 
APONTIS PHARMA marks further success in the roll-out of Single Pill therapy 
2021-07-12 / 07:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
APONTIS PHARMA marks further success in the roll-out of Single Pill therapy 
Monheim am Rhein, 12 July 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company 
specializing in Single Pills in the German market, continues to achieve success in the roll-out of its own product 
portfolio. 
The therapeutic effectiveness of Single Pills was verified in the study "Effect of Single pill combinations on T 
reatment Adherence and persistence as well as on clinical and pharmacoeconomic outcomes in the Real-world Treatment of 
hypertension, coronary heart disease, hyperlipidemia and in secondary prevention of cardiovascular events" (START), 
which was conducted in 2019. The purpose of the study, based on an anonymized health insurance data set, was to 
identify any differences in the forms of therapy. 
Ultimately, patients benefit from a Single Pill treatment versus a multi pill regimen. Instead of taking several 
individual medications for a hypertension indication, taking a Single Pill that combines up to three generic active 
pharmaceutical ingredients provides greater adherence. Therefore, the prescribed medication is taken more reliably when 
the dosage form is limited to a Single Pill. Single Pill therapy for hypertensive indications has received endorsement 
from AXA Krankenversicherung. In a letter to the insurants, the insurance company agreed to cover the costs of the use 
of Single Pill and support its use. 
The Single Pill therapy is evidence-based more efficient and ensures a more sustainable treatment success. The results 
of the START study also showed that the treatment of cardiovascular Single Pill therapy was associated with lower event 
rates such as stroke and myocardial infarction in German healthcare services. At the same time, fewer hospitalizations 
of corresponding patients were necessary. In turn, costs for health insurers are reduced and the overall therapy is 
less invasive. 
"Cardiovascular diseases are still the most common cause of death in Germany. With AXA Krankenversicherung's support, 
we are raising awareness of a proven, more efficient form of Single Pill therapy and focusing our activities on around 
22 million diagnosed, adult hypertensive patients in Germany alone. As a result, both patients benefit from more 
sustainable treatment success and health insurers from lower costs," says Karlheinz Gast, Chief Executive Officer of 
APONTIS PHARMA AG. 
About APONTIS PHARMA: 
APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two 
to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad 
portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 
2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as 
hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is 
located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network 
with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For 
additional information about APONTIS PHARMA, please visit www.apontis-pharma.de. 
APONTIS PHARMA AG 
Investor Relations 
ir@apontis-pharma.de 
T: +49 2173 89 55 4900 
F: +49 2173 89 55 1521 
Alfred-Nobel-Str. 10 
40789 Monheim am Rhein 
Deutschland 
apontis-pharma.de 
APONTIS PHARMA Presse-Kontakt 
CROSS ALLIANCE 
Sven Pauly 
Sara Pinto 
ir@apontis-pharma.de 
T: +49 89 125 09 0330 
www.crossalliance.de 
=---------------------------------------------------------------------------------------------------------------------- 
2021-07-12 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      APONTIS PHARMA AG 
              Alfred-Nobel-Str. 10 
              40789 Monheim 
              Germany 
E-mail:       info@apontis-pharma.de 
Internet:     https://apontis-pharma.de/ 
ISIN:         DE000A3CMGM5 
WKN:          A3CMGM 
Listed:       Regulated Unofficial Market in Frankfurt (Scale) 
EQS News ID:  1217386 
 
End of News   DGAP News Service 
=------------ 

1217386 2021-07-12

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1217386&application_name=news 
 

(END) Dow Jones Newswires

July 12, 2021 01:30 ET (05:30 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
APONTIS PHARMA AG 0.84% 24 Delayed Quote.0.00%
AXA 1.00% 23.255 Real-time Quote.18.11%
All news about APONTIS PHARMA AG
09/14APONTIS PHARMA : To Launch New Single Pill For Hypertension, Hyperlipidemia
MT
09/14APONTIS PHARMA : announces launch of new Single Pill for more efficient treatment of hyper..
EQ
09/14PRESS RELEASE : APONTIS PHARMA announces launch of new Single Pill for more efficient trea..
DJ
09/14Apontis Pharma AG Announces Launch of New Single Pill for More Efficient Treatment of H..
CI
08/11APONTIS PHARMA : builds on strong position and profitability in first half of 2021 - preli..
EQ
08/11PRESS RELEASE : APONTIS PHARMA builds on strong position and profitability in first half o..
DJ
07/28APONTIS PHARMA : reports accelerated growth in first half of 2021 - Single Pill revenues +..
EQ
07/28PRESS RELEASE : APONTIS PHARMA reports accelerated growth in first half of 2021 - Single P..
DJ
07/28Apontis Pharma AG Provides Earnings Guidance for the Financial Year 2021
CI
07/28Apontis Pharma AG Announces Unaudited Preliminary Earnings Results for the First Half o..
CI
More news
Financials
Sales 2021 49,3 M 57,7 M 57,7 M
Net income 2021 1,55 M 1,82 M 1,82 M
Net cash 2021 27,5 M 32,2 M 32,2 M
P/E ratio 2021 129x
Yield 2021 -
Capitalization 202 M 237 M 237 M
EV / Sales 2021 3,55x
EV / Sales 2022 2,98x
Nbr of Employees 195
Free-Float 100%
Chart APONTIS PHARMA AG
Duration : Period :
Apontis Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 23,80 €
Average target price 36,50 €
Spread / Average Target 53,4%
EPS Revisions
Managers and Directors
Karlheinz Gast Chief Executive Officer
Edin Hadzic Chairman-Supervisory Board
Olaf Randerath Head-Medical Affairs
Olaf Elbracht Member-Supervisory Board
Christopher Friedel Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
APONTIS PHARMA AG0.00%237
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972